Researchers identify potential drug target for frontotemporal dementia
Frontotemporal dementia is estimated to account for around 10-15% of all dementia cases in the US, with the majority of patients only surviving an average of 6-8 years after diagnosis.
Diabetes ages the mind and can bring on earlier dementia
Diabetes in middle age can age the mind by five years, potentially hastening the onset of dementia in later life, a new study has shown.
Maker of broccoli-derived cancer drug to float on London stock exchange
A company that is making a cancer drug derived from broccoli intends to float on the London stock exchange later this month.
GP ‘disgust’ at Care Quality Commission errors
GPs have told the BBC their reputations have been “tarnished by incompetence” from the health watchdog.
Text messaging service ‘helps people take their pills’
A text messaging service could help people remember to take the medicines they have been prescribed, say researchers.
Angela Rippon given honorary degree for raising dementia awareness
The former golden girl of BBCs flagship Nine OClock News bulletins who carved a mainstream television career after dancing alongside Morecambe and Wise in their 1976 Christmas Special, received an honorary doctor of civil law degree at Newcastle University.
New test could warn smokers if they are at risk of developing lung cancer
Scientists have discovered that cells taken from the mouth and nose react differently to infrared light in people vulnerable to the disease.
Drug can repair spinal cord injuries, study shows
A drug that can encourage nerves in the spinal cord to grow and repair injuries has been developed by US scientists.
Cabinet ministers take part in dementia exercise
David Cameron and his Cabinet took part in an exercise in which they imagined what it would be like to suffer from dementia, to help them understand the toll taken by the disease on completing everyday tasks.
AstraZeneca and Lilly move Alzheimer’s drug into big trial
AstraZeneca and Eli Lilly said on Monday they had started a large trial of their experimental Alzheimer’s drug, seen as a promising, but still risky, approach for slowing the memory-robbing disease.